

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

NCT07389499

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Grit Biotechnology
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (53)

- \. The participant or their legal representative voluntarily signs a written informed consent form, and is willing and able to comply with the procedures of this study.
 - \. Aged 18 to 75 years (inclusive) at the time of signing the informed consent, regardless of gender.
 - \. Positive expression of CD19 on B cells in peripheral blood is confirmed by flow cytometry.
 - \. Participants with IgA nephropathy (IgAN) at high risk of progression:
 - \. A definite pathological diagnosis of IgAN confirmed by renal biopsy (renal biopsy must be performed within 2 years prior to screening or during the screening period).
- ... and 48 more (see full listing online)

Exclusion (51)

- \. Participants with IgA nephropathy (IgAN) at high risk of progression:
 - a. Secondary IgAN (e.g., associated with active hepatitis B/hepatitis C infection, HIV, etc.).
 - \. Participants with ANCA-associated vasculitis (AAV)/ANCA-associated glomerulonephritis (AAGN):
 - Drug-induced or secondary AAV/AAGN.
 - Alveolar hemorrhage requiring invasive mechanical ventilation support at screening.
- ... and 46 more (see full listing online)

Locations (1 total)

Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China